Takeda Pharmaceutic-sp Adr (TAK) 13F Ownership Report (Q2 2026)

TAK ranks #1633 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

378 institutions disclose a position in TAK, but none treat it as a major bet — even Managed Asset Portfolios, LLC, its most concentrated holder, allocates just 3.3% of its own portfolio to it.

Fidelity has added to its TAK position for two straight quarters, increasing it by $90.6M to reach $153.9M today.

UBS Group AG has trimmed its TAK position for two straight quarters, cutting it by $49.7M while still holding $14.6M.

TAK is up 1.4% today, and institutions have been net buyers of $137.2M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

TAK reported a net loss of $152.1B in its latest fiscal year.

• Not yet profitable — net loss of $152.1B in the latest fiscal year
• Revenue declined 1.7% year over year
• Net income declined year over year, from $108.1B to -$152.1B
• Generated $1.0T in positive operating cash flow
• Current ratio of 1.09x — below the conventional 1.5x liquidity buffer
• Liabilities run 1.09x equity — within a conventional range